- Patients
- Clinical Research
- Clinical trials
- ProstACT-Global
2024-06-20T09:22:04.664Z
ProstACT-Global
ProstACT-Global
Prostate cancer
177Lu-DOTA-rosopatamab With Best Standard of Care (SoC) for the Second Line of Treatment for Metastatic Castrate-resistant Prostate Cancer, Which Expresses PSMA (PROSTACT)
177Lu-DOTA-rosopatamab With Best Standard of Care (SoC) for the Second Line of Treatment for Metastatic Castrate-resistant Prostate Cancer, Which Expresses PSMA (PROSTACT)
Trial overview
Clinical Area
Theranostics
Disease / Condition
Prostate cancer
Study Phase
III
Trial registration
Number: NCT04876651
GenesisCare Location(s)
GenesisCare Murdoch (Oncology)
GenesisCare Murdoch (Oncology)
:::
GenesisCare Location(s)